Robert S Svatek

List of Publications by Year
in descending order

Version: 2024-02-01

97 papers	3,957 citations	147726 31 h-index	128225 60 g-index
104 all docs	104 docs citations	104 times ranked	4459 citing authors

#	Article	IF	Citations
1	Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer. Cancer Immunology, Immunotherapy, 2023, 72, 125-136.	2.0	2
2	Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot randomized controlled trial. Prostate Cancer and Prostatic Diseases, 2022, 25, 531-538.	2.0	15
3	Reduced Dose Intravesical Bacillus Calmette-GuÃ©rin: Why It Might Not Matter. Bladder Cancer, 2022, 8, 113-117.	0.2	2
4	Diffusion of robot-assisted radical cystectomy: Nationwide trends, predictors, and association with continent urinary diversion. Arab Journal of Urology Arab Association of Urology, 2022, 20, 159-167.	0.7	2
5	Comparison of Robot-Assisted and Open Radical Cystectomy in Recovery of Patient-Reported and Performance-Related Measures of Independence. JAMA Network Open, 2022, 5, e2148329.	2.8	12
6	Histological variants of nonâ€“muscle invasive bladder cancer: Survival outcomes of radical cystectomy vs. bladder preservation therapy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 275.e1-275.e10.	0.8	4
7	Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Nonâ€“muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. European Urology, 2022, 81, 223-228.	0.9	8
8	Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitorâ€“Induced Synthetic Lethality. Cancer Research, 2022, 82, 2156-2170.	0.4	23
9	Clinical outcomes and patterns of populationâ€based management of urachal carcinoma of the bladder: An analysis of the National Cancer Database. Cancer Medicine, 2022, 11, 4273-4282.	1.3	4
10	A Decade of Robotic-Assisted Radical Nephrectomy with Inferior Vena Cava Thrombectomy: A Systematic Review and Meta-Analysis of Perioperative Outcomes. Journal of Urology, 2022, 208, 542-560.	0.2	11
11	Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncology, The, 2021, 22, 107-117.	5.1	172
12	The association between sarcopenia and bladder cancer-specific mortality and all-cause mortality after radical cystectomy: A systematic review and meta-analysis. Arab Journal of Urology Arab Association of Urology, 2021, 19, 98-103.	0.7	12
13	Association of TERT gene polymorphisms with clinical benign prostatic hyperplasia in a Chinese Han population of the Northwest region. Translational Andrology and Urology, 2021, 10, 692-702.	0.6	1
14	Bladder cancer cellâ€intrinsic PDâ€L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy. Cancer Medicine, 2021, 10, 2137-2152.	1.3	26
15	Rapamycin enhances BCG-specific Î³Î´ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study. , 2021, 9, e001941.		18
16	CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from Î±PD-L1 and include tissue-selective Î³Î´ T cell activation. , 2021, 9, e002051.		12
17	Correlates of refusal of radical cystectomy in patients with muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 236.e9-236.e20.	0.8	2
18	The utilization status of neoadjuvant chemotherapy in muscle-invasive bladder cancer: a systematic review and meta-analysis. Minerva Urology and Nephrology, 2021, 73, 144-153.	1.3	14

#	Article	IF	Citations
19	Neoadjuvant chemotherapy in bladder cancer: Clinical benefit observed in prospective trials computed with restricted mean survival times. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 435.e17-435.e22.	0.8	2
20	Y-Box Binding Protein 1 Regulates Angiogenesis in Bladder Cancer via miR-29b-3p-VEGFA Pathway. Journal of Oncology, 2021, 2021, 1-9.	0.6	7
21	Diagnostic and prognostic role of BTA, NMP22, survivin and cytology in urothelial carcinoma. Translational Cancer Research, 2021, 10, 3192-3205.	0.4	6
22	Bladder tumor ILC1s undergo Th17â€like differentiation in human bladder cancer. Cancer Medicine, 2021, 10, 7101-7110.	1.3	5
23	Î³Î´ T Cells Support Antigen-Specific Î±Î² T cellâ€“Mediated Antitumor Responses during BCG Treatment for Bladder Cancer. Cancer Immunology Research, 2021, 9, 1491-1503.	1.6	9
24	Effects of Mycobacterium bovis Calmette et GuÃ©rin (BCG) in oncotherapy: Bladder cancer and beyond. Vaccine, 2021, 39, 7332-7340.	1.7	13
25	CD122-targeted interleukin-2 and Î±PD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation. OncoImmunology, 2021, 10, 2006529.	2.1	1
26	Panâ€cancer analysis of iron metabolic landscape across the Cancer Genome Atlas. Journal of Cellular Physiology, 2020, 235, 1013-1024.	2.0	43
27	Screening logs from a pilot randomized controlled trial of radical cystectomy versus chemoradiation therapy for muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 4.e1-4.e6.	0.8	3
28	Carotenoid Intake and Circulating Carotenoids Are Inversely Associated with the Risk of Bladder Cancer: A Dose-Response Meta-analysis. Advances in Nutrition, 2020, 11, 630-643.	2.9	34
29	Identification of Differential Tumor Subtypes of T1 Bladder Cancer. European Urology, 2020, 78, 533-537.	0.9	77
30	Bladder Cancer Incidence and Survival in the United States and Texas Non-Latino Whites and Latinos. Bladder Cancer, 2020, 6, 497-506.	0.2	0
31	National Trends and Impact of Regionalization of Radical Cystectomy on Survival Outcomes in Patients with Muscle Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2020, 18, e762-e770.	0.9	4
32	Urinary Diversion Disparity Following Radical Cystectomy for Bladder Cancer in the Hispanic Population. Urology, 2020, 137, 66-71.	0.5	5
33	Pathological downstaging following radical cystectomy for muscle-invasive bladder cancer: Survival outcomes in the setting of neoadjuvant chemotherapy versus transurethral resection only. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 231-239.	0.8	4
34	Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup. Journal of Urology, 2020, 203, 522-529.	0.2	75
35	Health Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial: A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical Cystectomy. Journal of Urology, 2020, 204, 450-459.	0.2	26
36	Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUDâ€“SIU joint consultation on bladder cancer. World Journal of Urology, 2019, 37, 3-13.	1.2	42

#	Article	IF	Citations
37	ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. World Journal of Urology, 2019, 37, 51-60.	1.2	31
38	Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial. OncoImmunology, 2019, 8, 1614857.	2.1	27
39	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. Future Oncology, 2019, 15, 1683-1695.	1.1	35
40	Chemoradiation Vs Radical Cystectomy for Muscle-invasive Bladder Cancer: A Propensity Score-weighted Comparative Analysis Using the National Cancer Database. Urology, 2019, 133, 164-174.	0.5	15
41	Bacillus Calmetteâ€“GuÃ©rin treatment of bladder cancer. Current Opinion in Urology, 2019, 29, 181-188.	0.9	20
42	Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer. Cancer Immunology Research, 2019, 7, 466-475.	1.6	19
43	What is the Standard of Care for Pelvic Lymphadenectomy Performed at the Time of Radical Cystectomy?. European Urology, 2019, 75, 612-614.	0.9	11
44	Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model. Experimental Gerontology, 2018, 105, 146-154.	1.2	26
45	Role of immunotherapy in bacillus Calmetteâ€“GuÃ©rin-unresponsive nonâ€“muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 103-108.	0.8	20
46	Considerations for successful cancer immunotherapy in aged hosts. Experimental Gerontology, 2018, 107, 27-36.	1.2	33
47	Impact of age on outcomes of patients with nonâ€“muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 89.e1-89.e5.	0.8	6
48	Background and Update for S1602 â€œA Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-naÃ¯ve High-grade Non-muscle-invasive Bladder Cancer. European Urology Focus, 2018, 4, 522-524.	1.6	35
49	A Festschrift in Honor of Edward M. Messing, MD, FACS. Bladder Cancer, 2018, 4, S1-S43.	0.2	0
50	Cancer Immune Therapy: Prognostic Significance and Implications for Therapy of PD-1 in BCG-Relapsing Bladder Cancer. Annals of Surgical Oncology, 2018, 25, 2498-2499.	0.7	5
51	Adipose Tissue-Secreted Factors Alter Bladder Cancer Cell Migration. Journal of Obesity, 2018, 2018, 1-10.	1.1	13
52	Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet, The, 2018, 391, 2525-2536.	6.3	537
53	Editorial Comment. Journal of Urology, 2018, 199, 1451-1451.	0.2	1
54	Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review. European Urology Oncology, 2018, 1, 223-230.	2.6	25

#	Article	IF	Citations
55	Intratumoral CD56bright natural killer cells are associated with improved survival in bladder cancer. Oncotarget, 2018, 9, 36492-36502.	0.8	60
56	Bacillus Calmette-GuÃ©rin Manufacturing and SWOG S1602 Intergroup Clinical Trial. Journal of Urology, 2017, 197, 538-540.	0.2	10
57	Association of Distance to Treatment Facility With Survival and Quality Outcomes After Radical Cystectomy: A Multi-Institutional Study. Clinical Genitourinary Cancer, 2017, 15, 689-695.e2.	0.9	14
58	Efficacy of bacillus Calmette-GuÃ©rin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis. Journal of Urology, 2017, 198, 503-510.	0.2	92
59	Radical Cystectomy Compared to Combined Modality Treatment for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. International Journal of Radiation Oncology Biology Physics, 2017, 97, 1002-1020.	0.4	93
60	Intravesical rAdâ€“IFNÎ±/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerinâ€“Refractory or Relapsed Nonâ€“Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. Journal of Clinical Oncology, 2017, 35, 3410-3416.	0.8	124
61	Immune-Stimulatory Effects of Rapamycin Are Mediated by Stimulation of Antitumor Î³Î´ T Cells. Cancer Research, 2016, 76, 5970-5982.	0.4	33
62	Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study. European Urology, 2016, 69, 407-410.	0.9	51
63	Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-GuÃ©rin. European Urology, 2016, 69, 197-200.	0.9	136
64	Clinicopathological and Prognostic Value of Ki-67 Expression in Bladder Cancer: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0158891.	1.1	57
65	Novel Therapeutic Approaches for Recurrent Nonmuscle Invasive Bladder Cancer. Urologic Clinics of North America, 2015, 42, 159-168.	0.8	12
66	Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 65.e19-65.e25.	0.8	43
67	Long-term Outcomes of the FinnBladder-4 Study. European Urology, 2015, 68, 618-619.	0.9	2
68	Sequential Intravesical Mitomycin plus Bacillus Calmetteâ€“GuÃ©rin for Nonâ€“Muscle-Invasive Urothelial Bladder Carcinoma: Translational and Phase I Clinical Trial. Clinical Cancer Research, 2015, 21, 303-311.	3.2	26
69	Female Gender Is Associated With a Worse Survival After Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Competing Risk Analysis. Urology, 2014, 83, 863-868.	0.5	82
70	Alvimopan Accelerates Gastrointestinal Recovery After Radical Cystectomy: A Multicenter Randomized Placebo-Controlled Trial. European Urology, 2014, 66, 265-272.	0.9	186
71	Alvimopan, a Peripherally Acting Î¼-Opioid Receptor Antagonist, is Associated with Reduced Costs after Radical Cystectomy: Economic Analysis of a Phase 4 Randomized, Controlled Trial. Journal of Urology, 2014, 191, 1721-1727.	0.2	56
72	What is evaluation of hematuria by primary care physicians? Use of electronic medical records to assess practice patterns with intermediate follow-up. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 128-134.	0.8	53

#	Article	IF	Citations
73	The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease. European Urology, 2014, 66, 253-262.	0.9	418
74	Prospective External Validation of a Bladder Cancer Detection Model. Journal of Urology, 2014, 192, 1343-1348.	0.2	35
75	Extent of pelvic lymph node dissection during radical cystectomy: is bigger better?. Reviews in Urology, 2014, 16, 159-66.	0.9	13
76	Definition, Incidence, Risk Factors, and Prevention of Paralytic Ileus Following Radical Cystectomy: A Systematic Review. European Urology, 2013, 64, 588-597.	0.9	88
77	Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 480-486.	0.8	32
78	Alvimopan for prevention of postoperative paralytic ileus in radical cystectomy patients: a costâ€effectiveness analysis. BJU International, 2013, 111, 1054-1060.	1.3	38
79	Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?. World Journal of Urology, 2012, 30, 807-814.	1.2	16
80	Role and Extent of Lymphadenectomy During Radical Cystectomy for Invasive Bladder Cancer. Current Urology Reports, 2012, 13, 115-121.	1.0	16
81	Re: Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status. European Urology, 2012, 61, 1062-1063.	0.9	5
82	Cost Utility of Prostate Cancer Chemoprevention with Dutasteride in Men with an Elevated Prostate Specific Antigen. Cancer Prevention Research, 2011, 4, 277-283.	0.7	11
83	Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer. Expert Review of Anticancer Therapy, 2011, 11, 949-957.	1.1	9
84	The Effectiveness of Off-Protocol Adjuvant Chemotherapy for Patients with Urothelial Carcinoma of the Urinary Bladder. Clinical Cancer Research, 2010, 16, 4461-4467.	3.2	133
85	Age and Body Mass Index Are Independent Risk Factors for the Development of Postoperative Paralytic Ileus After Radical Cystectomy. Urology, 2010, 76, 1419-1424.	0.5	88
86	Risk Factor Analysis in a Contemporary Cystectomy Cohort Using Standardized Reporting Methodology and Adverse Event Criteria. Journal of Urology, 2010, 183, 929-934.	0.2	84
87	Novel therapeutics for patients with non-muscle-invasive bladder cancer. Expert Review of Anticancer Therapy, 2009, 9, 807-813.	1.1	8
88	High Risk Populations and Cystectomy Outcomes. Journal of Urology, 2009, 182, 10-11.	0.2	2
89	Re: Lymph Node Density Is Superior to TNM Nodal Status in Predicting Disease-Specific Survival After Radical Cystectomy for Bladder Cancer: Analysis of Pooled Data From MDACC and MSKCC. European Urology, 2008, 54, 690-691.	0.9	4
90	Role of Urinary Cathepsin B and L in the Detection of Bladder Urothelial Cell Carcinoma. Journal of Urology, 2008, 179, 478-484.	0.2	19

#	Article	IF	Citations
91	The Influence of Clinical and Pathological Stage Discrepancy on Cancer Specific Survival in Patients Treated for Renal Cell Carcinoma. Journal of Urology, 2006, 176, 1321-1325.	0.2	15
92	Magnetic resonance imaging characteristics of renal tumors after radiofrequency ablation. Urology, 2006, 67, 508-512.	0.5	26
93	Economic impact of screening for bladder cancer using bladder tumor markers: A decision analysis. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 338-343.	0.8	44
94	Pre-Treatment Nomogram for Disease-Specific Survival of Patients with Chemotherapy-Naive Androgen Independent Prostate Cancer. European Urology, 2006, 49, 666-674.	0.9	54
95	Soluble Fasâ€"A promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer, 2006, 106, 1701-1707.	2.0	54
96	The Cost of Prostate Cancer Chemoprevention: A Decision Analysis Model. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1485-1489.	1.1	30
97	Correlation of office-based cystoscopy and cytology with histologic diagnosis: How good is the reference standard?. Urology, 2005, 66, 65-68.	0.5	30